Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Profitability
This table compares Cardio Diagnostics and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
| Korro Bio | N/A | -114.26% | -68.57% |
Earnings and Valuation
This table compares Cardio Diagnostics and Korro Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $14,450.00 | 342.09 | -$6.50 million | ($2.92) | -0.57 |
| Korro Bio | $6.39 million | 32.99 | -$117.26 million | ($10.00) | -1.43 |
Cardio Diagnostics has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Cardio Diagnostics and Korro Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Korro Bio has a consensus target price of $16.50, suggesting a potential upside of 15.30%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Cardio Diagnostics.
Insider & Institutional Ownership
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Cardio Diagnostics has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.13, indicating that its stock price is 213% more volatile than the S&P 500.
Summary
Korro Bio beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
